common.study.topics.clinical

Adrenergic Antibodies in Postural Tachycardia Syndrome

common.study.values.description

POTS Adrenergic Ab (CIHR Aims #1&2)

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Phenylephrine

incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg

Drug - Isoproterenol

incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm

participant.views.study.view.additional

participant.views.study.view.scientific-title

The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)

common.study.values.clinical-trial-id

NCT02673996

participant.views.study.view.id

7e5KXb